Cerbios header

Cerbios header

X

[{"orgOrder":0,"company":"Bone Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bone Therapeutics receives Clinical Trial Application (CTA) approval for next clinical studies of its two lead candidates","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase II\/ Phase III","country":"BELGIUM","productType":"Large molecule","productStatus":"Approved","date":"March 2020","url1":"","url2":"","graph1":"Large molecule","graph2":"Bone Therapeutics"},{"orgOrder":0,"company":"Amzell B.V","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Phase 2\/3 Trial Suggests that Amzell\u2019s New Topical Treatment (AMZ001) for the Treatment of Knee Osteoarthritis Symptoms Is Effective","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase II\/ Phase III","country":"NETHERLANDS","productType":"Small molecule","productStatus":"Approved","date":"August 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Amzell B.V"},{"orgOrder":0,"company":"Xalud Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Xalud Therapeutics Appoints Diem Nguyen, Ph.D., as Chief Executive Officer","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase II\/ Phase III","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2021","url1":"","url2":"","graph1":"Cell and Gene therapy","graph2":"Xalud Therapeutics"},{"orgOrder":0,"company":"Xalud Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Xalud Therapeutics\u2019 XT-150, Achieves Multiple Clinical Milestones in Pathologic Inflammation and Neuroimmunology Therapeutic Areas","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase II\/ Phase III","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2021","url1":"","url2":"","graph1":"Cell and Gene therapy","graph2":"Xalud Therapeutics"},{"orgOrder":0,"company":"180 Life Sciences","sponsor":"Celltrion","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Celltrion Healthcare and 180 Life Sciences Enter Into Memorandum of Understanding for a Supply Agreement for the Ongoing Supply of Drug for Anti-TNF Product Trials for Novel Indications","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase II\/ Phase III","country":"U.S.A","productType":"Large molecule","productStatus":"Biosimilar","date":"September 2021","url1":"","url2":"","graph1":"Large molecule","graph2":"180 Life Sciences"},{"orgOrder":0,"company":"180 Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"180 Life Sciences Corp.Co-Founder Prof. Jagdeep Nanchahal Presents Keynote Address at the 2021 International Dupuytren Symposium, Including Top Line Data From the Phase 2b Clinical Trial","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase II\/ Phase III","country":"U.S.A","productType":"Large molecule","productStatus":"Biosimilar","date":"December 2021","url1":"","url2":"","graph1":"Large molecule","graph2":"180 Life Sciences"},{"orgOrder":0,"company":"180 Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"180 Life Sciences Provides Follow-Up Information on Oxford University and the Company\u2019s Successful Dupuytren\u2019s Phase 2b Clinical Trial Results","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase II\/ Phase III","country":"U.S.A","productType":"Large molecule","productStatus":"Biosimilar","date":"December 2021","url1":"","url2":"","graph1":"Large molecule","graph2":"180 Life Sciences"},{"orgOrder":0,"company":"180 Life Sciences","sponsor":"NIHR","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"180 Life Sciences with the University of Oxford Announce the Enrollment of the First Patient in a Trial of Anti-TNF for People with Early-Stage Frozen Shoulder","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase II\/ Phase III","country":"U.S.A","productType":"Large molecule","productStatus":"Biosimilar","date":"August 2022","url1":"","url2":"","graph1":"Large molecule","graph2":"180 Life Sciences"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Filters

×

FILTER:

filter

Company

filter

Sponsor

filter

Country

filter

Product Type

filter

News Type

Active Filter(s):

Filters

Reset Filter

All Developments

Product Type

Companies

180 Life Sciences

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

180 Life Sciences with the University of Oxford Announce the Enrollment of the First Patient in a Trial of Anti-TNF for People with Early-Stage Frozen Shoulder

Details:

Approximately 50% of patients with Dupuytren’s disease treated with Adalimumab also have frozen shoulder and Professor Nanchahal has previously shown that that TNF, a pro-inflammatory protein, is a key driver of the fibrosis in early-stage Dupuytren’s disease.

Lead Product(s): Adalimumab

Therapeutic Area: Musculoskeletal Product Name: Undisclosed

Highest Development Status: Phase II/ Phase III Product Type: Large molecule

Partner/Sponsor/Collaborator: NIHR

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable August 22, 2022

ASK
US

Upload
your Pipeline Activity

180 Life Sciences

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

180 Life Sciences Provides Follow-Up Information on Oxford University and the Company’s Successful Dupuytren’s Phase 2b Clinical Trial Results

Details:

Phase 2b clinical trial for Dupuytren’s disease using Humira (adalimumab), met both primary and secondary endpoints by significantly diminishing the hardness and size of the Dupuytren’s nodules.

Lead Product(s): Adalimumab

Therapeutic Area: Musculoskeletal Product Name: Humira

Highest Development Status: Phase II/ Phase III Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable December 06, 2021

ASK
US

Upload
your Pipeline Activity

180 Life Sciences

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

180 Life Sciences Corp.Co-Founder Prof. Jagdeep Nanchahal Presents Keynote Address at the 2021 International Dupuytren Symposium, Including Top Line Data From the Phase 2b ...

Details:

The top line data from the phase 2b clinical trial of Humira (Adalimumab) for patients with early-stage disease, met the primary end point of nodule hardness and the secondary end point of nodule size on ultrasound scan with statistically significant differences.

Lead Product(s): Adalimumab

Therapeutic Area: Musculoskeletal Product Name: Humira

Highest Development Status: Phase II/ Phase III Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable December 01, 2021

ASK
US

Upload
your Pipeline Activity

180 Life Sciences

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Celltrion Healthcare and 180 Life Sciences Enter Into Memorandum of Understanding for a Supply Agreement for the Ongoing Supply of Drug for Anti-TNF Product Trials for Nove...

Details:

Under the MOU with Celltrion Healthcare, supply of anti-TNF biosimilar drug used in the ongoing development for new indications including the first antibody biosimilar, Remsima®, infliximab for major autoimmune disorders such as rheumatoid arthritis and ulcerative colitis.

Lead Product(s): Infliximab

Therapeutic Area: Musculoskeletal Product Name: Remsima

Highest Development Status: Phase II/ Phase III Product Type: Large molecule

Partner/Sponsor/Collaborator: Celltrion

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Agreement September 20, 2021

ASK
US

Upload
your Pipeline Activity

Xalud Therapeutics

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Xalud Therapeutics’ XT-150, Achieves Multiple Clinical Milestones in Pathologic Inflammation and Neuroimmunology Therapeutic Areas

Details:

The primary efficacy evaluation of two potential therapeutic doses of XT-150 (150 and 450 μg) will be assessed at six months, followed by an additional six-month safety follow-up with the opportunity for a second injection. Topline results are expected in 4th quarter of 2021.

Lead Product(s): XT-150

Therapeutic Area: Musculoskeletal Product Name: XT-150

Highest Development Status: Phase II/ Phase III Product Type: Cell and Gene therapy

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable May 20, 2021

ASK
US

Upload
your Pipeline Activity

Xalud Therapeutics

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Xalud Therapeutics Appoints Diem Nguyen, Ph.D., as Chief Executive Officer

Details:

XT-150 is currently in a Phase II/III trial for osteoarthritis, and Nguyen expects to read out topline Phase IIb data in Q4. XT-150, is a locally injectable plasmid DNA gene therapy expressing Interleukin 10 (IL-10).

Lead Product(s): XT-150

Therapeutic Area: Musculoskeletal Product Name: XT-150

Highest Development Status: Phase II/ Phase III Product Type: Cell and Gene therapy

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable January 22, 2021

ASK
US

Upload
your Pipeline Activity

Amzell B.V

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Phase 2/3 Trial Suggests that Amzell’s New Topical Treatment (AMZ001) for the Treatment of Knee Osteoarthritis Symptoms Is Effective

Details:

This phase 2/3 multi-center, randomized, double-blind trial investigated the effect of a new 3.06% diclofenac sodium gel formulation (AMZ001) for the relief of knee OA pain, in 444 patients exposed to either AMZ001 once daily (QD), AMZ001 twice daily (BID) or placebo.

Lead Product(s): Diclofenac Sodium

Therapeutic Area: Musculoskeletal Product Name: AMZ001

Highest Development Status: Phase II/ Phase III Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable August 14, 2020

ASK
US

Upload
your Pipeline Activity

Bone Therapeutics

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Bone Therapeutics receives Clinical Trial Application (CTA) approval for next clinical studies of its two lead candidates

Details:

Two studies are the pivotal JTA-004 Ph III clinical study targeting osteoarthritic knee pain and Ph IIb study of its allogeneic cell therapy product, ALLOB, in difficult tibial fractures.

Lead Product(s): Plasma proteins,Hyaluronic Acid,Fast-acting analgesic

Therapeutic Area: Musculoskeletal Product Name: Undisclosed

Highest Development Status: Phase II/ Phase III Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable March 23, 2020

ASK
US

Upload
your Pipeline Activity

POST ENQUIRY